Fed. Circ. Rules Apotex's Fosamax Appeal Moot

Law360, New York (July 16, 2008, 12:00 AM EDT) -- Since generic versions of Merck & Co.'s osteoporosis drug Fosamax went on sale in February, a lawsuit involving Canadian generics maker Apotex Inc. is moot, the U.S. Court of Appeals for the Federal Circuit ruled Wednesday.

Apotex said it plans to begin marketing a generic version of Fosamax in next month.

Apotex had appealed an April 2007 ruling by the U.S. District Court for the District of Delaware that allowed Merck to drop a lawsuit accusing Apotex of infringing the patent for Fosamax. Merck sued after...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.